MedTrace Logo

HS-10502 Combination Treatment in Patients With Advanced Solid Tumors

NCT06769425 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 157

Last updated 2025-06-24

No results posted yet for this study

Summary

HS-10502 is a PARP1-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 Combination Treatment in subjects with advanced solid tumors.

Conditions

Interventions

DRUG

HS-10502 + NHA

HS-10502 + NHA

DRUG

HS-10502 + HS-20093

HS-10502 + HS-20093

DRUG

HS-10502+ Apatinib

HS-10502+ Apatinib

DRUG

HS-10502 + HS-20089

HS-10502 + HS-20089

DRUG

HS-10502 + Platinum + Bevacizumab

HS-10502 + Platinum + Bevacizumab

DRUG

HS-10502 + nab-paclitaxel or Docetaxel or Irinotecan

HS-10502 + nab-paclitaxel or Docetaxel or Irinotecan

DRUG

HS-10502 + Bevacizumab

HS-10502 + Bevacizumab

Sponsors & Collaborators

  • Jiangsu Hansoh Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-07
Primary Completion
2026-05-07
Completion
2026-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06769425 on ClinicalTrials.gov